Sudarshan Pharma Industries Ltd has notified stock exchanges about a GST inspection, search and seizure operation that commenced at its registered office on February 21, 2026. The operation was initiated by the Goods & Service Tax Department, Mumbai, Maharashtra.

Regulatory Compliance and Disclosure

The company made the disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, through a formal communication dated February 22, 2026. Sudarshan Pharma Industries emphasized its commitment to transparency and regulatory compliance in informing stakeholders about this development.

Company Response and Cooperation

The pharmaceutical company has outlined its approach to handling the GST inspection:

Operational Continuity

Despite the ongoing inspection, Sudarshan Pharma Industries has assured stakeholders that its business operations have continued without disruption during the GST Department's activities. This indicates the company's ability to maintain operational stability while addressing regulatory requirements.

Future Updates and Material Developments

The company has committed to providing timely updates to exchanges regarding any material developments arising from the inspection. Upon conclusion of the GST operation, relevant information will be shared with stakeholders in due course, ensuring continued transparency throughout the process.

The disclosure reflects the company's adherence to regulatory obligations and its proactive approach to keeping investors and market participants informed about significant corporate developments that may impact its operations.

Sudarshan Pharma Industries Limited has announced the successful obtainment of two critical certifications for its API manufacturing facility, marking a significant milestone in the company's quality assurance journey. The certifications underscore the company's commitment to maintaining global quality benchmarks and robust manufacturing practices in the pharmaceutical sector.

Certification Details

The company has secured two important certifications for its manufacturing facility located at Plot No. D 22, TGIIC-IALA, IDA-Medchal, Medchal-Malkajgiri District, Hyderabad, Telangana - 501401:

Validity and Timeline

Both certifications carry significant validity periods, providing the company with long-term compliance assurance:

Strategic Significance

These certifications represent a crucial development for Sudarshan Pharma Industries Limited's manufacturing capabilities. The GMP certification ensures that the company's manufacturing processes meet international standards for pharmaceutical production, while the ISO 9001:2015 certification validates the company's quality management systems.

The certifications cover the manufacturing of API intermediates and Active Pharmaceutical Ingredients, which are critical components in pharmaceutical production. This achievement positions the company as a reliable and compliant manufacturer in the competitive API and pharmaceutical intermediates segment.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating the company's commitment to transparent communication with stakeholders. The certifications are subject to satisfactory surveillance audits to maintain their validity throughout the certification period.

These quality certifications are expected to enhance the company's credibility with existing and potential clients, particularly in international markets where GMP and ISO certifications are often mandatory requirements for pharmaceutical suppliers.